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Trends in management and outcomes of COPD patients in
primary care, 2000–2009: a retrospective cohort study
Gareth D James1,2, Gavin C Donaldson2, Jadwiga A Wedzicha2 and Irwin Nazareth1
BACKGROUND: Since the introduction of the Quality and Outcomes framework, there has been some evidence of improvement in
the management of chronic obstructive pulmonary disease (COPD) patients in the United Kingdom through increasing rates of
smoking cessation advice and immunisations against inﬂuenza. However, it is unknown whether disease-speciﬁc management
criteria, disease outcomes and diagnosis have improved.
AIMS: To describe changes in the management and outcomes of patients with COPD in UK general practice between
2000 and 2009.
METHODS: The study was done on a retrospective cohort using data from The Health Improvement Network UK primary care
database. We calculated age at diagnosis of COPD and death, total number of short-term oral corticosteroid courses and
consultations, and proportion of patients with very severe COPD and on triple inhaled therapy for each year between 2000
and 2009.
RESULTS: We identiﬁed 92,576 patients with COPD. The mean age at COPD diagnosis decreased from 68.1 years in 2000 to 66.7
years in 2009. The mean age at death increased from 78.2 years in 2000 to 78.8 years in 2009. The number of prescribed courses of
oral corticosteroids increased from 0.6 in 2000 to 0.8 in 2009. The number of consultations increased from 9.4 in 2004 to 11.3 in
2009. The risk of having very severe COPD decreased from 9.4% in 2004 to 6.8% in 2009. The likelihood of patients with very severe
COPD receiving triple therapy increased from 25% in 2004 to 59% in 2009.
CONCLUSIONS: The trends suggest that management and outcomes observed in patients with COPD may have improved since
the year 2000.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) has a substantial
burden on individual patients and health services worldwide.1
Patients suffer breathlessness, exacerbations and reduced quality
of life.2 In the UK, there are an estimated 900,000 people with
COPD, and the disease costs the National Health Service (NHS)
over £253 million each year.3
There have been a number of initiatives that should have led to
continuous improvements in the spirometric assessment and
management of patients with COPD in General Practice.4 Possibly,
the most important was the Quality and Outcomes Framework in
2004, which is a voluntary incentive scheme for general practices
in the UK that rewards patient care. Since its introduction, UK
practices have continued to increase their achievement of Quality
and Outcomes Framework indicators.5 Practices are paid if they
demonstrate a register of patients with COPD and that these
patients have spirometry performed and inhaler technique
checked in the preceding 15 months and were given inﬂuenza
immunisation. Other initiatives include publication of COPD
management guidelines by the National Institute for Health and
Clinical Excellence guidelines.2 Continuing professional develop-
ment would help increase awareness of these initiatives. There is
some evidence of improvement through increasing rates of
smoking cessation advice6 and immunisations against inﬂuenza.7
However, it is not known whether disease-speciﬁc management
criteria and disease outcomes of COPD patients have changed
over time.
Early diagnosis of COPD was a speciﬁc aim of the National
Institute for Health and Clinical Excellence guidelines. There has
been some progress,4 but two-thirds of the UK population are
unaware of the term COPD8 and thus may not seek help as they
confuse the symptoms with age-related disability. Good manage-
ment should involve regular patient–clinician consultations,
prescription of inhaled therapy and encouragement to seek
treatment for exacerbations when short courses of oral corticos-
teroids may be required.2,9 Triple inhaled therapy, the combina-
tion of a long-acting β2-agonist (LABA), a long-acting muscarinic
antagonist (anticholinergic) bronchodilator (LAMA), and an
inhaled corticosteroid (ICS) inhaler, has received much interest
recently,10,11 but further evidence from randomised controlled
trials is required to further quantify their efﬁcacy and to determine
which patient population they should be prescribed to. The
National Institute for Health and Clinical Excellence guidelines
recommend this therapy is provided to patients with persistent
exacerbations or breathlessness despite treatment with a LAMA or
LABA+ICS combination.
Using data from The Health Improvement Network (THIN)
primary care database, we aimed to describe trends in the
management and outcomes of patients with COPD in UK general
practice since the year 2000. Management was assessed by age at
diagnosis of COPD and death, and total number of consultations
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and short-term oral corticosteroid courses prescribed. We also
examined trends in the proportion of patients with very severe
COPD and on triple therapy, as these impose a large ﬁnancial
burden on health services and knowledge of any increase will be
useful for heath-service planning.
MATERIALS AND METHODS
Data source
In the UK, general practitioners (GPs) record medical diagnosis and
symptoms, health indicators such as smoking status and prescribed
medicines during consultations with patients. In all, 98% of the population
is registered with a GP12 and COPD is primarily managed in general practice.
The THIN primary care database includes anonymised medical and
prescribing records from 6% of the UK population (details concerning the
number of practices and active patients can be found at http://csdmruk.
cegedim.com/our-data/statistics.shtml). The database is broadly representa-
tive of UK general practice in terms of gender, age and smoking status,13,14
and it has been validated for pharmacoepidemiological research.15
Recorded diagnoses and symptoms are classiﬁed using Read codes.16
Prescription data are comparable with national statistics,17 and over 98% of
prescriptions are redeemed.18 The database includes quintiles of the
Townsend score,19 a composite measure of social deprivation (occupation,
unemployment, car ownership, overcrowding) based on data from the 2001
Census and mapped to a patient’s postal code. The ﬁfth quintile is most
deprived and the ﬁrst quintile is least deprived. Accurate data recording in
THIN is ensured by only including practices newly involved in THIN when
they meet acceptable recording standards and practice standardised
mortality rates match externally collected data from the National death
registration statistics.20 The prevalence, demographics, smoking habits and
mortality of patients with COPD in the database match national data.4
Study population
We included all patients who were aged between 35 and 89 years
registered in THIN between 2000 and 2009. Patients entered the study on
the latest date of either their 35th birthday or 1 January 2000, when they
registered with the practice or the practice met the quality standard for
data recording. Data were collected until the earliest date of their 90th
birthday, death, transfer to another practice or 31 December 2009.
Our sample of COPD patients included all eligible patients with a
diagnosis of COPD based on the Quality and Outcomes Framework Read
codes for COPD. These codes have been shown to be helpful in selecting a
subset of patients whose prevalence, geographical distribution, age and
gender distribution match other national COPD surveys4 and have been
used in other COPD studies.21,22 Patients were considered to have the
disease from the date of diagnosis—although the patients may have had
the disease for some time before.
We extracted information on the latest recorded smoking status (active/
non/ex-smoker), height and quintiles of Townsend deprivation scores
for all patients. We also extracted the forced expiratory volume in 1s (FEV1)
and forced vital capacity values (FVC) before 2004 and annual measure-
ments between 2004 and 2009. When information on FEV1 was
unavailable, it was carried forward from previous years. FEV1 and FVC
measurements outside a 0.3–7.0 litre range were considered invalid. All
oral corticosteroid prescriptions of ⩽14 days and prescriptions of a LAMA
(tiotropium), LABA (salmeterol or formoterol), ICS (ﬂuticasone or
budesonide), LABA+ICS combination (salmeterol + ﬂuticasone or
formoterol + budesonide) and medical diagnosis records were extracted
for all patients with COPD from their date of diagnosis. Oral corticosteroids
were used as a proxy for exacerbations. Triple therapy was deﬁned as co-
prescriptions of a LAMA (tiotropium) and an ICS/LABA combination inhaler
(either salmeterol + ﬂuticasone (Seretide), or formoterol + budesonide
(Symbicort)). Prescriptions of these compounds with three separate
inhalers were also included in case the combination was recorded
separately. A third combination therapy, Fostair, had not received a UK
license by 2009. Tiotropium was not available until 2002 so annual
estimates were only calculated from 2004 onwards. We are aware that
there are other ICSs, but we did not examine these as they are not part of
the LABA + ICS combination inhalers that constitute triple therapy.
The criteria devised by Global Initiative for Chronic Obstructive Lung
Disease were used to classify the severity of disease.9 Predicted FEV1 was
estimated using age, sex and height, using the method in Quanjer et al.23
Severity was classiﬁed as follows: ‘mild’ if FEV1⩾ 80% predicted, ‘moderate’ if
FEV1 ⩾ 50% and o80% predicted, ‘severe’ if FEV1 ⩾ 30% and o50%
predicted, and ‘very severe’ if FEV1 o30% predicted.
Management and outcome indices
We considered six indices of management and outcomes: age at diagnosis
and death, total number of short-term oral corticosteroid courses and
consultations, the proportion of patients with very severe COPD and the
proportion of patients with very severe COPD on triple therapy. The indices
were calculated for patients with COPD in each calendar year.
The age of death was calculated for all patients and all COPD patients
who had died at the age of ⩾ 65 years, as below this age deaths are
unlikely to be tobacco related. The age of patients with COPD in each
calendar year was also calculated.
Spirometry was not well recorded before 2004, and thus the severity
grade by the Global Initiative for Chronic Obstructive Lung Disease
classiﬁcation was only calculated from 2004 onwards. The proportion of
patients in each category was then calculated for each calendar year. A
patient consultation was identiﬁed as a single day with one or more
medical diagnosis codes for COPD recorded by the patient’s GP.
Statistical analysis
The characteristics of patients with COPD and the whole population were
tabulated. The annual prevalence of COPD was calculated by dividing the
total follow-up time contributed by the COPD population by the sum of
the follow-up time of the whole population within a given year. Annual
incidence rates of COPD were calculated by dividing the total number of
newly diagnosed COPD patients by the sum of the whole population
follow-up time within a given year. Follow-up time (patient-years) was
preferred to number of patients as it takes account of the amount of time
each patient is alive or registered with their practice. The mean and
corresponding 95% conﬁdence intervals (CIs) were calculated for each
quality of care index in 2000, 2004 and 2009.
We assessed changes over time in the management and outcome
indices. Mean age at diagnosis and death between 2000 and 2009 were
assessed using linear regression. Poisson generalised estimating equations
were constructed with unstructured covariance to estimate the annual rate
of change in the number of oral corticosteroids and consultations per
patient-year between 2000 and 2009 and the probability of a patient with
very severe COPD receiving triple therapy in each calendar year between
2004 and 2009. The generalised estimating equation method was chosen
Table 1. Characteristics of patients with COPD and the whole
population
Variable Category All COPD
Total patient no. — 2,839,694 92,576
Agea (mean, years) — 54.8 70.5
Agea (%) 35–39 21.4 0.6
40–49 24.2 3.8
50–59 19.8 12.9
60–69 15.0 27.3
70–79 11.5 33.8
80–89 8.2 21.6
Gender (%) Male 49.1 53.8
Female 50.9 46.2
Smoking (%) Non 53.2 14.4
Active 21.2 32.6
Ex 25.7 53.0
Townsend quintile (%) 1 (least deprived) 27.1 16.5
2 22.8 18.1
3 20.8 21.3
4 17.6 23.8
5 (most deprived) 11.8 20.3
FEV1 (mean, l) — — 1.4
FVC (mean, l) — — 2.4
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in 1s; FVC, forced vital capacity.
aAge was determined at the mid-point of each patient’s observation
period.
Management and outcome trends in COPD patients
GD James et al
2
npj Primary Care Respiratory Medicine (2014) 14015 © 2014 Primary Care Respiratory Society UK/Macmillan Publishers Limited
to account for repeated measurements within patients. A logistic model
was constructed to estimate the probability of having very severe COPD in
2004 and 2009 relative to any other severity classiﬁcation. All models were
constructed without adjustment, and once again with adjustment for age,
sex and Townsend quintile.
All statistical analyses were conducted using Stata version 12.0
(Stata, College Station, TX, USA).
Ethics
The THIN scheme for obtaining and providing anonymous patient data to
researchers was approved by the National Health Service South-East
Multicenter Research Ethics Committee (MREC) in 2002.
RESULTS
Patient characteristics
In total, there were 2,839,694 patients in 419 general practices
who were aged between 35 and 89 years between 2000 and 2009;
92,576 (3%) had a clinical record of COPD. The average follow-up
time from COPD diagnosis was 3 years and 10 months. The mean
age of prevalent COPD patients was 71 years, and 54% of patients
were male. In comparison with the general population, patients
with COPD were older and from more socially deprived areas
(Table 1). The recorded prevalence of COPD increased from 24
individuals per 1,000 patient-years in 2000 to 36 in 2009,
equivalent to a 50% increase over the 10-year period (Figure 1).
However, the diagnosis of new COPD cases remained fairly
constant at 3.5 individuals per 1,000 patient-years.
For the COPD population, data were 100% complete for age
and sex, 95% for deprivation data as measured by Townsend
quintiles, 91% for height and smoking status, 72% for FEV1 values
and 52% for FVC values. Annual FEV1 recording increased each
year, from 47% of patients in 2004 to 81% in 2009.
Summary measures for the management and outcome indices
The mean age at which COPD was diagnosed decreased from 68.1
years (95% CI, 67.8, 68.4) in 2000 to 66.7 years in 2009 (66.4, 67.0;
Table 2 and Figure 2a). The mean age at death of COPD patients
increased from 78.2 years (77.9, 78.6) in 2000 to 78.8 years (78.6,
79.1) in 2009. Similarly, the mean age at death of all patients
increased from 79.5 years (79.3, 79.6) in 2000 to 80 years (79.9,
80.1) in 2009. Consequently, the mean age of prevalent COPD
patients remained fairly constant over the period, varying
between 70 and 70.7 years.
In 2004, 10% of patients had ‘very severe’ COPD, as deﬁned by
the Global Initiative for Chronic Obstructive Lung Disease
spirometric criteria,9 and this decreased to 7% in 2009 (Table 2
and Figure 2b). The use of triple inhaled therapy between 2004
and 2009 increased from 7 to 21% in mild COPD, from 10 to 29%
in moderate COPD, from 17 to 45% in severe COPD and from 25 to
59% in very severe COPD (Table 2, Figure 2c).
In total, 462,301 courses of oral corticosteroids were prescribed
to patients with COPD between 2000 and 2009. The mean number
of oral corticosteroid prescriptions per patient-year increased from
0.6 (95% CI, 0.6, 0.6) in 2000 to 0.8 (0.8, 0.8) in 2009 (Table 2 and
Figure 2d).
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Figure 1. Prevalence and incidence rates of chronic obstructive
pulmonary disease between 2000 and 2009.
Table 2. Management and outcome indices in 2000, 2004 and 2009 for COPD and all patients
Outcome 2000 2004 2009
COPD patients N Mean (95% CI) N Mean (95% CI) N Mean (95% CI)
Age at diagnosis (years) 5,993 68.1 (67.8, 68.4) 7,834 67.4 (67.2, 67.7) 5,774 66.7 (66.5, 66.7)
Age at death (years) 1,195 78.2 (77.9, 78.6) 2,178 78.6 (78.3, 78.8) 2,582 78.8 (78.6, 79.1)
N % (95% CI) N % (95% CI) N % (95% CI)
Very severe COPD (%) — — 19,034 9.9 (9.5, 10.3) 45,654 6.8 (6.6, 7.0)
Triple therapy (%)
Mild COPD — — 2,650 6.7 (5.8, 7.7) 7,668 21.1 (20.2, 22.1)
Moderate COPD — — 8,515 9.5 (8.9, 10.1) 22,747 28.6 (28.0, 29.1)
Severe COPD — — 5,985 17.4 (16.4, 18.4) 12,137 45.2 (44.3, 46.1)
Very severe COPD — — 1,884 25.4 (23.5, 27.5) 3,094 58.6 (56.8, 60.3)
N Per patient (95% CI) N Per patient (95% CI) N Per patient (95% CI)
Oral corticosteroid prescriptions 16,851 0.6 (0.6, 0.6) 33,924 0.7 (0.7, 0.7) 49,203 0.8 (0.8, 0.8)
Consultations 16,851 9.4 (9.4, 9. 4) 33,924 10.5 (10.4, 10.5) 49,203 11.3 (11.3, 11.3)
All patients N Mean (95% CI) N Mean (95% CI) N Mean (95% CI)
Age at death (years) 10,569 79.5 (79.3, 79.6) 15,449 79.53 (79.4, 79.6) 16,179 80.0 (79.9, 80.1)
Abbreviations: CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease.
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The COPD patients attended 3,688,949 consultations between
2000 and 2009. The mean number of consultations per patient-
year increased from 9.4 (9.4, 9.4) in 2000 to 11.3 (11.3, 11.3) in 2009
(Table 2 and Figure 2e).
Hypothesis testing for the management and outcome indices
There was little difference in the regression coefﬁcients for annual
change between the unadjusted models and the models adjusted
for age, sex and Townsend quintile (Tables 3a and b). Between
2000 and 2009, each additional year was associated with a 0.18-
year decrease (95% CI, 0.15, 0.21) in the mean age at diagnosis, a
0.07-year increase (0.04, 0.10) in the mean age at death, a 4.9%
(4.7%, 5.1%) increase in the number of prescribed oral corticoster-
oids and a 2.8% (2.8%, 2.9%) increase in the number of
consultations. Patients had 0.67 (0.64, 0.72) times the risk of
having very severe COPD in 2009 compared with 2004. Between
2004 and 2009, the likelihood of very severe COPD patients
receiving triple therapy increased by 15% (14%, 17%) each year.
DISCUSSION
Main ﬁndings
This study provides evidence that the management and outcomes
of patients with COPD in UK primary care has changed between
2000 and 2009. GPs are identifying COPD earlier, and patients with
the disease are being monitored more regularly and treated more
in accordance with the recent National Institute for Health and
Clinical Excellence guidelines. These improvements may have
contributed to the improved longevity and reduced severity of
disease in the COPD patients we observed.
Interpretation of ﬁndings in relation to previously published work
The estimate of COPD prevalence obtained from this study is
considerably lower than that obtained by conducting spirometry
on the general population, indicating that COPD may be
underdiagnosed in primary care. This study and others24–27 have
found that the prevalence of COPD is increasing, which may
indicate that small improvements in diagnosis are being made.
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Figure 2. Management and outcome indices in chronic obstructive pulmonary disease (COPD): 2000–2009. (a) Mean age of prevalent COPD
cases, at COPD diagnosis and at death. (b) Proportion of patients in each COPD severity category. (c) Proportion of COPD patients who received
triple therapy. (d) Number of oral corticosteroid prescriptions per COPD patient-year. (e) Number of COPD consultations per patient-year.
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Table 3. Management and outcome indices hypothesis testing: (a) all patients with COPD; (b) all patients with very severe COPD
Index Adjustment Period Period, age, sex, townsend
Coef (95% CI) P-value Coef (95% CI) P-value
(a)
Mean age at diagnosis: linear, n= 65,900 Annual change − 0.18 (−0.21, − 0.15) o0.01 − 0.19 (−0.22, − 0.16) o0.01
Sex — — 0.21 (0.04, 0.38) 0.02
Townsend 1 — — 1.00
Townsend 2 — — − 0.49 (−0.78, − 0.19)
Townsend 3 — — − 1.64 (−1.92, − 1.35)
Townsend 4 — — − 2.23 (−2.50, − 1.95)
Townsend 5 — — − 3.74 (−4.03, − 3.45)
Townsend missing — — − 1.80 (−2.23, − 1.37) o0.01
Mean age at death: linear, n= 20,932 Annual change 0.08 (0.04, 0.11) o0.01 0.07 (0.04, 0.1) o0.01
Sex — — 0.56 (0.39, 0.73) o0.01
Townsend 1 (Ref) — — 1.00
Townsend 2 — — − 0.19 (−0.48, 0.11)
Townsend 3 — — − 0.48 (−0.77, − 0.19)
Townsend 4 — — − 1.03 (−1.3, − 0.75)
Townsend 5 — — − 1.5 (−1.79, −1.21)
Townsend missing — — 0.22 (−0.22, 0.67) o0.01
Proportion of patients with very severe
COPD: odds ratio, n= 52,311
Annual change 0.66 (0.62, 0.70) o0.01 0.67 (0.64, 0.72) o0.01
Age — — 0.99 (0.99, 1.00) o0.01
Sex — — 0.52 (0.48, 0.55) o0.01
Townsend 1 (Ref) — — 1.00
Townsend 2 — — 0.97 (0.88, 1.08)
Townsend 3 — — 1.01 (0.91, 1.11)
Townsend 4 — — 1.09 (0.99, 1.20)
Townsend 5 — — 1.10 (1.00, 1.22)
Townsend missing — — 0.99 (0.85, 1.17) 0.03
No. of oral corticosteroids: incident rate ratio, n= 92,576 Annual change 1.05 (1.05, 1.05) o0.01 1.05 (1.05, 1.05)a o0.01
Age — — 1.01 (1.01, 1.01) o0.01
Sex — — 1.21 (1.20, 1.23) o0.01
Townsend 1 (Ref) — — 1.00
Townsend 2 — — 1.03 (1.01, 1.06)
Townsend 3 — — 1.07 (1.05, 1.10)
Townsend 4 — — 1.12 (1.10, 1.15)
Townsend 5 — — 1.20 (1.18, 1.23)
Townsend missing — — 1.08 (1.05, 1.12) o0.01
No. of consultations: incident rate ratio, n= 92,576 Annual change 1.03 (1.03, 1.03) o0.01 1.03 (1.03, 1.03)b o0.01
Age — — 1.01 (1.01, 1.01) o0.01
Sex — — 1.08 (1.08, 1.08) o0.01
Townsend 1 (Ref) — — 1.00
Townsend 2 — — 0.99 (0.98, 1.00)
Townsend 3 — — 1.03 (1.03, 1.04)
Townsend 4 — — 1.01 (1.01, 1.02)
Townsend 5 — — 1.01 (1.00, 1.01)
Townsend missing — — 1.09 (1.08, 1.10) o0.01
(b)
Proportion of patients receiving triple therapy: incident
rate ratio, n= 6,456
Annual change 1.15 (1.14, 1.17) o0.01 1.16 (1.14, 1.18) 0.00
Age — — 0.99 (0.99, 0.99) 0.00
Sex — — 0.94 (0.88, 1.01) 0.09
Townsend 1 (Ref) — — 1.04 (0.92, 1.16)
Townsend 2 — — 1.06 (0.95, 1.19)
Townsend 3 — — 1.07 (0.96, 1.19)
Townsend 4 — — 1.03 (0.92, 1.15)
Townsend 5 — — 0.98 (0.82, 1.17)
Townsend missing — — 1.16 (1.14, 1.18) 0.77
Abbreviations: CI, conﬁdence interval; Coef, coefﬁcient; COPD, chronic obstructive pulmonary disease.
a1.049 (1.047, 1.051) to 3 dp.
b1.028 (1.028, 1.029) to 3 dp.
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Our sample does not represent the prevalence of COPD in the
community as deﬁned by FEV1 values, as many people may have
the disease on this basis but are not diagnosed because their
respiratory symptoms are mild. Notably, in terms of symptomatic
COPD, Shahab et al.24 found 2.7% of the general population
presented with COPD in 2004, which is similar to our prevalence
estimate. Smith et al.4 also reported that the prevalence of COPD
in UK general practice was considerably lower than that obtained
using spirometry and that the prevalence increased between 2003
and 2005. The increase in prevalence of COPD and the total
number of consultations made by these patients corresponds to
COPD having an increasing burden on general practice.
COPD patients have beneﬁted from small improvements in
longevity, similar to that seen in the general population.28 It is
likely that this is due to better public health advice and
improvements in health care that are as good as those seen in
the other major causes of death, and that most COPD patients die
from co-morbidities. Earlier diagnosis of COPD is an important
ﬁnding, as early intervention may control symptoms, improve the
quality of life and reduce the impact of exacerbations.8 Increased
awareness of COPD in recent years has been noted in other
studies4 and may partly explain the earlier identiﬁcation of COPD.
The proportion of patients with severe and very severe COPD in
the primary care population has decreased over time. The carrying
forward of FEV1 records from previous years does not explain this
decrease, as the same analysis using the raw data indicates an
additional 1% fall in the proportion of patients with severe and
very severe COPD. The decreasing severity could be due to an
expansion in the COPD population of mild and moderate disease
through earlier detection and diagnosis, or improved therapy
preventing disease progression. We observed a marked increase
in the use of triple therapy. As expected, patients with more
severe COPD have experienced a larger increase in the use of
triple therapy in accordance with current guidelines.9 We also
found that up to a third of patients with mild or moderate COPD
severity were on triple therapy, which is outside current
recommendations unless the patients experience frequent exacer-
bations. The ECLIPSE observational study has reported that 22% of
patients worldwide with moderate COPD severity would be
categorised as a frequent exacerbator, as they suffer two or more
exacerbations per year.29 Although we cannot be certain from our
data, it is possible that the patients we observed with mild or
moderate COPD severity who were prescribed triple inhaled
therapy are perhaps being treated as per the current guidelines.
Given the expansion in the proportion of patients with mild and
moderate COPD, it is unlikely that the mean number of
exacerbations per patient has increased over time.30 The rise in
the number of oral corticosteroids per year could be explained by
patients being encouraged to seek GP help when they have an
exacerbation or the greater likelihood of GPs prescribing oral
corticosteroids for exacerbations.
Strengths and limitations of this study
This study has many strengths. The data were large (THIN
comprises 6% of the UK population), longitudinal and generali-
sable to the UK general practice population and contained
information on patient characteristics, diagnosis and prescriptions,
which allowed us to assess many measures of quality of care over
time. In addition, we used validated codes for identifying COPD
patients. The study, however, was limited by the lack of
information on hospitalisations and exacerbations, which would
have provided a more comprehensive picture of changes in
patient management. In addition, it may be advantageous to have
investigated triple therapy involving ICS agents other than
ﬂuticasone or budesonide, but this would have been considerably
more complicated. We also did not assess whether triple therapy
was appropriately prescribed or not. A further limitation is the use
of oral corticosteroid prescriptions as a proxy for exacerbations, as
a large proportion of exacerbations may be treated with
antibiotics alone. However, we considered oral corticosteroids to
provide greater sensitivity, as antibiotics can be prescribed for
many reasons other than a pulmonary infection. It is also possible
that changes in the management of co-morbid conditions may
have inﬂuenced the results, for example, improvements in the
care of cardiovascular disease may have improved the longevity of
COPD patients, whereas the increased incidence of diabetes in the
UK population may have had the reverse effect.
There will be a number of reasons for the differences in the
management of COPD patients in UK general practice observed in
this study and other studies,5–7 including the Quality and
Outcomes Framework, clearer management guidelines, profes-
sional development and recognition of the need to screen
patients for this disease. Their implementation and effect would
overlap, and therefore it was not possible to ascribe improve-
ments to any single initiative. It is not yet known whether setting
clearer guidelines for appropriate management will improve
outcomes such as mortality.
Implications for future research, policy and practice
Increasing awareness of COPD and management initiatives have
changed the outcomes in COPD. Current and any new initiatives
should continue to be supported.
CONCLUSION
Longitudinal trends since the year 2000 suggest that patients with
COPD are being diagnosed, assessed and treated more. This might
partly explain why COPD patients appear to be living longer and
have reduced severity of disease.
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